muvalaplin
Jump to navigation
Jump to search
Indications
- elevations of lipoprotein(a) [[[A144164|Lp(a)]]] > 50 mg/dL
Dosage
- 100-800 mg daily
Adverse effects
- not associated with tolerability concerns
Mechanism of action
- selective small molecule inhibitor of Lp(a) formation
- lowers Lp(a) levels as much as 65% after daily administration for 14 days
More general terms
References
- ↑ Nicholls SJ, Nissen SE, Fleming C et al Muvalaplin, an Oral Small Molecule Inhibitor of Lipoprotein(a) Formation. A Randomized Clinical Trial. JAMA. Published online August 28, 2023. PMID: https://www.ncbi.nlm.nih.gov/pubmed/37638695 https://jamanetwork.com/journals/jama/fullarticle/2808864
- ↑ Owens B New Pill Successfully Lowers Lp(a) Levels Medscape. Nov 19, 2024 https://www.medscape.com/viewarticle/new-pill-successfully-lowers-lp-levels-2024a1000l13